{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:45:34Z","timestamp":1759333534946},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,1,4]],"date-time":"2009-01-04T00:00:00Z","timestamp":1231027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Poly\u2010<jats:sc>l<\/jats:sc>\u2010lactic acid (PLA) injections modestly increase objectively assessed facial thickness but not facial soft tissue volume (FSTV) over 24 weeks. The durability of this response has not been well defined objectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HIV\u2010infected lipoatrophic adults were randomized to four open\u2010label PLA treatments administered every 2 weeks from week 0 (immediate group, <jats:italic>n<\/jats:italic>=50) or from week 24 (deferred group, <jats:italic>n<\/jats:italic>=50). Endpoints included FSTV assessed by computed tomography, facial lipoatrophy severity, quality of life (QoL) and safety. Analyses were by intention to treat.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between weeks 24 and 48, soft tissue thickness increased modestly in injection planes, at the maxillary [mean 0.9\u2003mm; 95% confidence interval (CI) 0.3\u20131.5\u2003mm; <jats:italic>P<\/jats:italic>=0.007] and base of nasal septum levels (mean 0.4\u2003mm; 95% CI 0.1\u20130.8; <jats:italic>P<\/jats:italic>=0.021), but not in untreated areas (<jats:italic>P<\/jats:italic>=0.79 and <jats:italic>P<\/jats:italic>=0.24). PLA durability assessed at week 48 in immediate group participants showed a mean change in FSTV of 14\u2003cm<jats:sup>3<\/jats:sup> (95% CI\u22121 to 29\u2003cm<jats:sup>3<\/jats:sup>; <jats:italic>P<\/jats:italic>=0.060) and increased tissue depth at the maxillary (<jats:italic>P<\/jats:italic>&lt;0.0001), base of nasal septum (<jats:italic>P<\/jats:italic>&lt;0.0001) and mandibular (<jats:italic>P<\/jats:italic>=0.0035) levels. At week 48, clinicians and patients subjectively assessed facial lipoatrophy severity as reduced in immediate participants (83 and 91%, respectively), and the Mental Health scale score of the Short Form\u201036 Health Survey improved significantly in immediate participants relative to deferred participants (<jats:italic>P<\/jats:italic>=0.027). Subcutaneous injection\u2010site nodule incidence at 48 weeks was 10%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PLA treatment benefits were durable, with objectively assessed modest increases in facial volume and tissue thickness sustained over 48 weeks in injection planes but not in other facial areas. Improvements in some QoL domains were maintained.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00667.x","type":"journal-article","created":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T02:06:31Z","timestamp":1231121191000},"page":"163-172","source":"Crossref","is-referenced-by-count":11,"title":["Poly\u2010<scp>l<\/scp>\u2010lactic acid for HIV\u20101 facial lipoatrophy: 48\u2010week follow\u2010up"],"prefix":"10.1111","volume":"10","author":[{"given":"D","family":"Carey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GD","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the FLASH Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11518-5"},{"key":"e_1_2_6_4_2","first-page":"2441","article-title":"Failure to maintain long\u2010term adherence to highly active antiretroviral therapy","volume":"15","author":"Duran S","year":"2001","journal-title":"the role of lipodystrophy"},{"key":"e_1_2_6_5_2","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral\u2010na\u00efve patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00004"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00005"},{"key":"e_1_2_6_8_2","first-page":"1029","article-title":"Reversibility of lipoatrophy in HIV\u2010infected patients 2 years after switching from a thymidine analogue to abacavir","volume":"18","author":"Martin A","year":"2004","journal-title":"the MITOX Extension Study"},{"key":"e_1_2_6_9_2","first-page":"116","article-title":"Restorative interventions for HIV facial lipoatrophy","volume":"10","author":"Carey D","year":"2008","journal-title":"AIDS Rev"},{"key":"e_1_2_6_10_2","first-page":"2471","article-title":"Polylactic acid implants (New\u2010Fill)\u00ae to correct facial lipoatrophy in HIV\u2010infected patients","volume":"17","author":"Valantin M\u2010A","year":"2003","journal-title":"results of the open-label study VEGA"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00190.x"},{"key":"e_1_2_6_12_2","first-page":"1336","article-title":"Safety and efficacy of poly\u2010l\u2010lactic acid injections in persons with HIV\u2010associated facial lipoatrophy","volume":"32","author":"Mest D","year":"2006","journal-title":"the US experience"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.056"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000152834.02912.98"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.3.329"},{"key":"e_1_2_6_16_2","first-page":"753","article-title":"Comparison of three different interventions for the correction of HIV\u2010associated facial lipoatrophy","volume":"10","author":"Guaraldi G","year":"2005","journal-title":"a prospective study"},{"key":"e_1_2_6_17_2","first-page":"829","article-title":"Reconstructive treatment for antiretroviral\u2010associated facial lipoatrophy","volume":"20","author":"Negredo E","year":"2006","journal-title":"a prospective study comparing autologous fat and synthetic substances"},{"key":"e_1_2_6_18_2","first-page":"833","article-title":"Long\u2010term psychometric outcomes of facial lipoatrophy therapy","volume":"21","author":"Orlando G","year":"2007","journal-title":"forty-eight-week observational, nonrandomized study"},{"key":"e_1_2_6_19_2","unstructured":"EngelhardP.Efficacy of subdermal injections of poly\u2010l\u2010lactic acid for HIV\u2010associated facial lipoatrophy.3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro Brazil July 2005 [Abstract TuPe24C07]."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318158bec9"},{"key":"e_1_2_6_21_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_6_22_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"Carr A","year":"2003","journal-title":"a case-control study"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"volume-title":"Users' Manual for the Multidimensional Body\u2010Self Relations Questionnaire","year":"2000","author":"Cash TF","key":"e_1_2_6_24_2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/339074"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1988.01670060015008"},{"key":"e_1_2_6_27_2","first-page":"1135","article-title":"Tissue response and in vivo degradation of selected polyhydroxyacids","volume":"27","author":"Gogolewski S","year":"1993","journal-title":"polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB\/VA)"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-003-3022-1"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281c6148d"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200308150-00004"},{"key":"e_1_2_6_31_2","first-page":"207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy","volume":"288","author":"Carr A","year":"2002","journal-title":"a randomized trial"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000247574.33998.03"},{"key":"e_1_2_6_33_2","first-page":"469","article-title":"Measuring outcomes in aesthetic surgery","volume":"111","author":"Ching S","year":"2003","journal-title":"a comprehensive review of the literature"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00342.x"},{"key":"e_1_2_6_35_2","first-page":"385","article-title":"Poly\u2010L\u2010lactic acid","volume":"3","author":"Woerle B","year":"2004","journal-title":"a temporary filler for soft tissue augmentation"},{"volume-title":"Sculptra\u2122 (Injectable Poly\u2010L\u2010Lactic Acid). Prescribing Information","year":"2006","author":"Dermik Laboratories.","key":"e_1_2_6_36_2"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00667.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00667.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:32:00Z","timestamp":1696865520000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00667.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,19]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00667.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00667.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2009,2,19]]}}}